Systemic Inflammatory Markers of Resectable Colorectal Cancer Patients with Different Mismatch Repair Gene Status

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248–5257.9823339
   PubMed Web of Science ®Google Scholar
• Sameer AS, Nissar S, Fatima K. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. Eur J Cancer Prev. 2014;23(4):246–257. doi:10.1097/CEJ.000000000000001924614649
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 2004;20(4–5):199–206. doi:10.1155/2004/36868015528785
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–3226. doi:10.1200/JCO.2009.27.182520498393
   PubMed Web of Science ®Google Scholar
• Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–19. doi:10.1200/JCO.19.0210731725351
   PubMed Web of Science ®Google Scholar
• Li J, Xu Q, Luo C, et al. Clinicopathologic characteristics of resectable colorectal cancer with mismatch repair protein defects in Chinese population: retrospective case series and literature review. Medicine (Baltimore). 2020;99(24):e20554. doi:10.1097/MD.000000000002055432541478
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.0210531682550
   PubMed Web of Science ®Google Scholar
• Yu C, Hong H, Zhang S, et al. Identification of key genes and pathways involved in microsatellite instability in colorectal cancer. Mol Med Rep. 2019;19(3):2065–2076. doi:10.3892/mmr.2019.984930664178
   PubMed Web of Science ®Google Scholar
• Stadtmann A, Block H, Volmering S, et al. Cross-talk between Shp1 and PIPKIgamma controls leukocyte recruitment. J Immunol. 2015;195(3):1152–1161. doi:10.4049/jimmunol.150060626101325
   PubMed Web of Science ®Google Scholar
• Scanzello CR. Chemokines and inflammation in osteoarthritis: insights from patients and animal models. J Orthop Res. 2017;35(4):735–739. doi:10.1002/jor.2347127808445
   PubMed Web of Science ®Google Scholar
• Hurt B, Schulick R, Edil B, et al. Cancer-promoting mechanisms of tumor-associated neutrophils. Am J Surg. 2017;214(5):938–944. doi:10.1016/j.amjsurg.2017.08.00328830617
   PubMed Web of Science ®Google Scholar
• Wu L, Awaji M, Saxena S, et al. IL-17–CXC chemokine receptor 2 axis facilitates breast cancer progression by up-regulating neutrophil recruitment. Am J Pathol. 2020;190(1):222–233. doi:10.1016/j.ajpath.2019.09.01631654638
   PubMed Web of Science ®Google Scholar
• Wunderlich CM, Ackermann PJ, Ostermann AL, et al. Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment. Nat Commun. 2018;9(1):1646. doi:10.1038/s41467-018-03773-029695802
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. doi:10.1158/2159-8290.CD-14-086325358689
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.270324048123
   PubMed Web of Science ®Google Scholar
• Lofroos AB, Kadivar M, Resic Lindehammer S, et al. Colorectal cancer-infiltrating T lymphocytes display a distinct chemokine receptor expression profile. Eur J Med Res. 2017;22(1):40. doi:10.1186/s40001-017-0283-829020986
   PubMed Web of Science ®Google Scholar
• Morrell CN, Pariser DN, Hilt ZT, et al. The platelet napoleon complex—small cells, but big immune regulatory functions. Annu Rev Immunol. 2019;37(1):125–144. doi:10.1146/annurev-immunol-042718-04160730485751
   PubMed Web of Science ®Google Scholar
• Ribeiro LS, Migliari Branco L, Franklin BS. Regulation of innate immune responses by platelets. Front Immunol. 2019;10:1320.31244858
   PubMed Web of Science ®Google Scholar
• Marques P, Collado A, Martinez-Hervas S, et al. Systemic inflammation in metabolic syndrome: increased platelet and leukocyte activation, and key role of CX3CL1/CX3CR1 and CCL2/CCR2 axes in arterial platelet-proinflammatory monocyte adhesion. J Clin Med. 2019;8(5):708. doi:10.3390/jcm8050708
   PubMed Web of Science ®Google Scholar
• De Smedt L, Lemahieu J, Palmans S, et al. Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. Br J Cancer. 2015;113(3):500–509. doi:10.1038/bjc.2015.21326068398
   PubMed Web of Science ®Google Scholar
• Pine JK, Morris E, Hutchins GG, et al. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour. Br J Cancer. 2015;113(2):204–211. doi:10.1038/bjc.2015.8726125452
   PubMed Web of Science ®Google Scholar
• Park JH, Powell AG, Roxburgh CSD, et al. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer. 2016;114(5):562–570. doi:10.1038/bjc.2016.1726859693
   PubMed Web of Science ®Google Scholar
• Kong P, Wang J, Song Z, et al. Circulating lymphocytes, PD-L1 expression on tumor-infiltrating lymphocytes, and survival of colorectal cancer patients with different mismatch repair gene status. J Cancer. 2019;10(7):1745–1754. doi:10.7150/jca.2518731205530
   PubMed Web of Science ®Google Scholar
• Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019;7:e7132. doi:10.7717/peerj.713231632844
   PubMed Web of Science ®Google Scholar
• Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer. Ann Surg. 2020;272(2):342–351. doi:10.1097/SLA.000000000000323932675548
   PubMed Web of Science ®Google Scholar
• Climent M, Ryan ÉJ, Stakelum Á, et al. Systemic inflammatory response predicts oncological outcomes in patients undergoing elective surgery for mismatch repair-deficient colorectal cancer. Int J Colorectal Dis. 2019;34(6):1069–1078. doi:10.1007/s00384-019-03274-630993458
   PubMed Web of Science ®Google Scholar
• Haram A, Boland MR, Kelly ME, et al. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review. J Surg Oncol. 2017;115(4):470–479. doi:10.1002/jso.2452328105646
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545. doi:10.1016/S0140-6736(00)04046-011229684
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.02520303878
   PubMed Web of Science ®Google Scholar
• Keller DS, Windsor A, Cohen R, et al. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019;23(1):3–13. doi:10.1007/s10151-019-1926-230701345
   PubMed Web of Science ®Google Scholar
• Mirzaei SA, Dinmohammadi F, Alizadeh A, et al. Inflammatory pathway interactions and cancer multidrug resistance regulation. Life Sci. 2019;235:11682531494169
   PubMed Web of Science ®Google Scholar